This study investigates the therapeutic potential of combining doxo with HDAC inhibitors, specifically Tas, an HDAC4 inhibitor, and PCI, a selective HDAC8 inhibitor, in osteosarcoma treatment. Here, HDAC9 is linked to osteosarcoma.